A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 424 participants.
Also called NCT02597049
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 424 participants
- Sponsor
- Registry
-
NCT02597049 -
2015-002095-24
-
- Other papers using this trial's data
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Czechia, Germany, Hungary, Israel, Mexico, Puerto Rico, Spain
- Registry status
- Completed
Technical summary
Registry record NCT02597049. Randomized; double masking; primary purpose treatment. Start 2015-11 (registry gives no type); primary completion 2017-02 (actual). Results posted on 2018-04-27.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus
- Acronym
- AWARD-10
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Dulaglutide
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- SGLT2 inhibitor
- Intervention (Drug)
- Metformin
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct02597049- Content hash
585e2e52035bdab8e54ed231dbc44d9e36bd1d6ee9e6e45ddd19c35486bd7a9d